Pure Global
NCT03888729

Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)

Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)
Partners in Health·Phase 4·ClinicalTrials.gov·drug
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatitis C, Chronic
Drug/Device/Intervention
sofosbubir/velpatasvir
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Partners in Health
Location
Kigali, Rwanda
Timeline & enrollment
Phase
Phase 4
Start date
Aug 26, 2019
End date
Mar 01, 2020
Enrollment
100 participants
Primary outcome

Proportion of participants with sustained viral response 12 weeks after discontinuation of study treatment (SVR12),Proportion of patients treated with SOF/VEL FDC and SOF/VEL/VOX FDC with a new grade 3 or 4 adverse event as defined by the DAIDS Scales or with premature study drug discontinuation due to an adverse event

Summary

The main purpose of the study is to determine the antiviral efficacy and evaluate the safety
 and tolerability of sofosbuvir/ velpatasvir (SOF/VEL) and sofosbuvir/ velpatasvir/
 voxilaprevir (SOF/VEL/VOX) used to treat individuals with chronic hepatitis C virus infection
 in Rwanda adults.

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic hepatitis, unspecifiedChronic viral hepatitisChronic viral hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03888729
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03888729 through Pure Global AI's free database. This Phase 4 trial is sponsored by Partners in Health and is currently status unknown. The study focuses on Hepatitis C, Chronic. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.